Foresight Mental Health is a Berkeley, California-based outpatient mental health provider that pairs clinicians - psychiatrists, therapists and prescribers - with software, data and wearables to deliver personalized, insurance-covered care. Founded by two UC Berkeley computer-science students, the company offers therapy, psychiatry, child and adolescent services, ADHD testing, intensive outpatient programs and TMS across in-person clinics and telehealth, with the stated mission of improving access to high-quality mental health care.
On May 14, 2026, logistics AI company Pallet launched Pallet Forge, an 'agent factory' that compresses the build-and-deploy cycle for production-grade logistics AI agents from roughly six months to six weeks. Authored by co-founder and CEO Sushanth Raman, the announcement frames Forge as Pallet's answer to the industry's pilot-to-production gap — citing the MIT finding that only 5% of enterprise GenAI pilots generate measurable P&L impact. Forge works by connecting to a customer's systems (TMS, WMS, ERP, EDI, email, and legacy AS400), encoding operational rules and carrier preferences inferred from historical data instead of hand-written SOPs, and running thousands of simulations to tune agent accuracy automatically. Early proof points include Everest Transportation running on 20,000+ customer-specific encoded memories and Eassons Transport Group hitting 98% touchless processing after going live in 40 days — with subsequent customers onboarded in as little as 48 hours.
Neural Galaxy (also operating as Galaxy Brain Scientific) is a Beijing-based brain science company building a precision, non-invasive neuromodulation platform. Its proprietary personalized Brain Functional Sectors (pBFS) technology maps over 200 functional regions of an individual brain, then guides targeted transcranial magnetic stimulation with millimeter accuracy. Founded in 2019 by Harvard and MIT neuroscientists with serial entrepreneur Coach Wei, the company is running clinical and registration trials across depression, Parkinson's, Alzheimer's, autism and aphasia, and has raised roughly $93M to date.
Shipwell is an Austin-based software company building an AI-integrated transportation management system (TMS) that unifies shipment planning, real-time visibility, automation, and settlement in one cloud platform. Founded in 2016 by Greg Price and Jason Traff, it helps shippers and logistics teams across food & beverage, manufacturing, and distribution move freight with less manual work. After selling its brokerage arm to CloudTrucks in 2024, Shipwell now operates as a pure-play SaaS provider and has been named a Visionary in the Gartner Magic Quadrant for TMS for five consecutive years.
Augment builds Augie, an AI teammate purpose-built for logistics. The San Francisco company automates the phone calls, emails, portal logins, and back-office workflows that bog down freight brokers, shippers, and carriers - and has raised $110M in under a year to scale it.
Pallet is a San Francisco AI startup building an 'AI workforce' for the logistics industry. Its flagship product, CoPallet, automates back-office freight workflows - order entry, quoting, document parsing, portal updates - that have historically required armies of human operators. Founded in 2020 by ex-Retool engineer Sushanth Raman, the company serves freight brokers, 3PLs, warehouses and carriers including STG Logistics, Mallory Alexander, Knight, Swift and Lineage.
Don Vaughn, Ph.D. is the Co-Founder and CEO of Ampa Health, a Palo Alto-based neurotechnology company building FDA-cleared portable TMS (transcranial magnetic stimulation) devices that compress 36 days of depression treatment into a single day. A Stanford-educated physicist turned UCLA neuroscientist, Vaughn has built a career at the intersection of brain science, machine learning, and accessibility - detoured, notably, through a DJ career that landed him a #28 iTunes Dance chart hit featuring Nick Lachey. His TEDx talk on neurohacking has surpassed one million views. Ampa raised an oversubscribed $8.5M pre-A round in October 2025, achieved FDA clearance for its Ampa One device in February 2025, and is targeting 5,000 patient remissions by end of 2026 - with a long-term audacious goal of a billion remissions in ten years.